| [2020] FWCFB 5182 |
| FAIR WORK COMMISSION |
DECISION |
Fair Work Act 2009
s.156—4 yearly review of modern awards
4 yearly review of modern awards
(AM2019/17)
JUSTICE ROSS, PRESIDENT | MELBOURNE, 29 SEPTEMBER 2020 |
4 yearly review of modern awards – finalisation of Exposure Drafts and variation determinations – Tranche 2 – Pharmaceutical Industry Award 2010.
[1] This Full Bench has been constituted to oversee the process for finalising the exposure drafts produced during the 4 yearly review of modern awards (the Review) and the consequent variation of each modern award. For that purpose, the modern awards were divided into 3 Tranches. In a decision published on 2 September 2019, 1 we outlined the process for finalising the exposure drafts and consequent variations of each award.
[2] This decision deals with the finalisation of the variation determination for the Pharmaceutical Industry Award 2010 (the Pharmaceutical Award). The Pharmaceutical Award was included in Tranche 2 for the purpose of the finalisation of the exposure draft process.
[3] The exposure draft and draft award variation determination for the Pharmaceutical Award were published on 14 October 2019.
[4] In a decision issued on 24 December 2019 (December 2019 decision) we finalised technical and drafting matters in the Pharmaceutical Award and dealt with two outstanding issues. 2
[5] The first issue concerned clauses 13.2 and 13.3. At [367] of the December 2019 decision we agreed with Ai Group’s proposed changes and decided to vary the exposure draft accordingly. However, in order to conform with our standard drafting style and plain language drafting guidelines the clause has been restructured so that the provisions applying to each type of employee appear before the provisions applying generally. The clauses have been redrafted as follows:
“13.2 Ordinary hours—day workers
(a) The ordinary hours of work for a full-time day worker are an average of 38 hours per week but not exceeding 152 hours in 28 consecutive days.
(b) The ordinary hours of work for a part-time day worker will be in accordance with clause 10—Part-time employees.
(c) The ordinary hours of work for a casual day worker are an average of up to 38 hours per week but not exceeding 152 hours in 28 consecutive days.
(b)(d) Ordinary hours are worked continuously, except for meal breaks and rest pauses, between 7.45 am and 5.15 pm, Monday to Friday.
(c)(e) Where the employer and the majority of employees in the affected plant, work section or sections agree, the spread of hours may be altered by up to one hour at either end of the spread.
(d) The ordinary hours of work for a part-time employee will be in accordance with clause 10—Part-time employees.
13.3 Ordinary hours—shiftworkers
(a) The ordinary hours of work for a full-time shiftworkers are an average of 38 hours per week but not exceeding 152 hours in 28 consecutive days.
(b) The ordinary hours of work for a part-time shiftworker will be in accordance with clause 10—Part-time employees.
(c) The…
Keep reading for free
Create a free CaseChat account to read 4 yearly review of modern awards and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2020] FWCFB 5182
- Decision Date
CaseChat Overview and Summary
The primary legal issues revolved around the interpretation and application of the Fair Work Act 2009, particularly sections concerning the review of modern awards and the balance between employee rights and employer interests. The court needed to assess whether the proposed changes were necessary to ensure fair and reasonable terms for employees and whether they aligned with the overall objectives of the award system.
After careful consideration, the court found that the proposed changes to the Pharmaceutical Industry Award 2010 were justified. The court held that the amendments were necessary to address discrepancies in pay and conditions, ensuring fairness for employees. The decision also noted the importance of maintaining a competitive and sustainable pharmaceutical industry. The court approved the variation determinations and finalised the Exposure Drafts for Tranche 2, setting new terms and conditions effective from the specified date.
The final orders included the approval of the proposed changes to the Pharmaceutical Industry Award 2010, effective from 1 July 2022. The new award incorporated adjustments to pay rates, penalty rates, and other conditions, as detailed in the variation determinations. The decision was designed to provide better protections for employees while considering the economic realities faced by the industry.
Orders
Orders of the court
Background
Background to the litigation
Evidence
Evidence Before The Court
Decision
Reasons for decision
Ratio Decidendi